Pharmacogenomics of gemcitabine metabolism: Functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinases

Drug Metabolism and Disposition

Volumn 41, Issue 3, 2013, Pages 541-545

  Guo, Yingying ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DRUG METABOLITE; GEMCITABINE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CATALYSIS; CONTROLLED STUDY; DEAMINATION; DRUG CLEARANCE; DRUG METABOLISM; ENZYME KINETICS; ENZYME SUBSTRATE; ESCHERICHIA COLI; GENETIC VARIABILITY; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOTRANSFORMATION; CATALYSIS; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; GENETIC VARIATION; GENOTYPE; HUMANS; KINETICS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHARMACOGENETICS; PHENOTYPE; PHOSPHORYLATION; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84874029063     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048769     Document Type: Article

References (17)

1. Ciccolini J, Mercier C, Dahan L, and André N (2011) Integrating pharmacogenetics into gemcitabine dosing-time for a change? Nat Rev Clin Oncol 8:439-444.
2. Costanzi S, Vilar S, Micozzi D, Carpi FM, Ferino G, Vita A, and Vincenzetti S (2011) Delineation of the molecular mechanisms of nucleoside recognition by cytidine deaminase through virtual screening. ChemMedChem 6:1452-1458.
3. Deenen MJ, Cats A, Beijnen JH, and Schellens JH (2011) Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist 16: 820-834.
4. Erculj N, Kovac V, Hmeljak J, Franko A, Dodic-Fikfak M, and Dolzan V (2012) The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenet Genomics 22:58-68.
5. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, and McLeod HL (2004) Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 4:307-314.
6. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM, and Weinshilboum RM (2006) Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 12: 1794-1803.
7. Kocabas NA, Aksoy P, Pelleymounter LL, Moon I, Ryu JS, Gilbert JA, Salavaggione OE, Eckloff BW, Wieben ED, and Yee V, et al. (2008) Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos 36:1951-1959.
8. Laliberté J, Marquez VE, and Momparler RL (1992) Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-29-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 30:7-11.
9. Mini E, Nobili S, Caciagli B, Landini I, and Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17 (Suppl 5):v7-v12.
10. Miwa M, Eda H, Ura M, Ouchi KF, Keith DD, Foley LH, and Ishitsuka H (1998) High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 29-deoxycytidine antimetabolite, 29-deoxy-29- methylidenecytidine. Clin Cancer Res 4:493-497.
11. Parmar S, Seeringer A, Denich D, Gärtner F, Pitterle K, Syrovets T, Ohmle B, and Stingl JC (2011) Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells. Pharmacogenomics 12:503-514.
12. Sabini E, Ort S, Monnerjahn C, Konrad M, and Lavie A (2003) Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 10:513-519.
13. Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, and Slapak CA, et al. (2008) Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 14: 3477-3486.
14. Vincenzetti S, Cambi A, Neuhard J, Garattini E, and Vita A (1996) Recombinant human cytidine deaminase: expression, purification, and characterization. Protein Expr Purif 8:247-253.
15. Vincenzetti S, Mariani PL, Cammertoni N, Polzonetti V, Natalini P, Quadrini B, Volpini R, and Vita A (2004) Isoenzymatic forms of human cytidine deaminase. Protein Eng Des Sel 17: 871-877.
16. White JC and Capizzi RL (1991) A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells. Cancer Res 51:2559-2565.
17. Yue L, Saikawa Y, Ota K, Tanaka M, Nishimura R, Uehara T, Maeba H, Ito T, Sasaki T, and Koizumi S (2003) A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13:29-38.